CORMORANT ASSET MANAGEMENT LP
Q2 2023 Form 13-F
BOSTON, MASSACHUSETTS
CIK 0001583977
· CRD 167820
· SEC-registered investment adviser
Consolidated report · includes
1 manager
since Q4 2013
$1.8B Reported Value Total
CORMORANT ASSET MANAGEMENT, LP reports 12 total accounts under management (AUM). There are 12 discretionary accounts valued at $3,117,053,633, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
7 funds
· $3.8B gross asset value
Hedge Fund: $2.2B · Private Equity Fund: $1.6B
Source: Form ADV filed 2026-05-27
Reported value
$1.8B
Quarter over quarter
+31.5%
Holdings
61
Top-10 concentration
60.0%
Filing Structure
Reports holdings for
- Chen Bihua · File #028-15950 · since Q4 2013
Key People
Form ADV owners & control persons
Bihua Chen
MANAGING MEMBER & CHIEF EXECUTIVE OFFICER
Nebojsa Obradovic
CHIEF COMPLIANCE OFFICER & GENERAL COUNSEL
Caleb Jonathan Tripp
CHIEF FINANCIAL OFFICER & CHIEF OPERATING OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2023 13F record
Q2 2023 13F filing summary
| Period of report | June 30, 2023 |
|---|---|
| Filed | August 14, 2023 |
| Form | 13F-HR |
| Reported value | $1.8B |
| Positions | 61 |
| Change in reported value | +17.6% |
| New positions | 9 |
| Exited positions | 20 |
| Position turnover | 35.8% |
| Top-10 concentration | 60.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
50 | $2.0B |
|
Q1 2026 13F
Filed May 15, 2026
|
46 | $2.0B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
32 | $2.2B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
36 | $1.4B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
42 | $1.3B |
|
Q1 2025 13F
Filed May 15, 2025
|
42 | $1.3B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
48 | $1.8B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
45 | $1.9B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
47 | $1.7B |
|
Q1 2024 13F
Filed May 15, 2024
|
56 | $2.3B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
47 | $2.1B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
49 | $1.7B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
61 | $1.8B |
|
Q1 2023 13F
Filed May 15, 2023
|
72 | $1.5B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
72 | $1.5B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
72 | $1.4B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
79 | $1.3B |
|
Q1 2022 13F
Filed May 16, 2022
|
77 | $1.3B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
78 | $1.7B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
88 | $2.5B |
31 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | $415.2M | 23.26% |
| 2 | AMAM AMBRX BIOPHARMA INC | $158.3M | 8.87% |
| 3 | APLS APELLIS PHARMACEUTICALS INC | $119.3M | 6.69% |
| 4 | BMEA BIOMEA FUSION INC | $78.4M | 4.39% |
| 5 | BBIO BRIDGEBIO PHARMA INC | $71.7M | 4.02% |
| 6 | ACLX ARCELLX INC | $63.2M | 3.54% |
| 7 | IMRX IMMUNEERING CORP | $42.6M | 2.39% |
| 8 | CBAY CYMABAY THERAPEUTICS INC | $41.6M | 2.33% |
| 9 | PTGX PROTAGONIST THERAPEUTICS INC | $41.4M | 2.32% |
| 10 | ELVN ENLIVEN THERAPEUTICS INC | $39.5M | 2.21% |
| 11 | PCVX VAXCYTE INC | $33.2M | 1.86% |
| 12 | DSGN DESIGN THERAPEUTICS INC | $32.4M | 1.82% |
| 13 | ZNTL ZENTALIS PHARMACEUTICALS INC | $30.9M | 1.73% |
| 14 | ERAS ERASCA INC | $29.8M | 1.67% |
| 15 | RNA AVIDITY BIOSCIENCES INC | $29.0M | 1.62% |
| 16 | CABA CABALETTA BIO INC | $28.7M | 1.61% |
| 17 | EYPT EYEPOINT PHARMACEUTICALS INC | $27.8M | 1.56% |
| 18 | OLMA OLEMA PHARMACEUTICALS INC | $27.8M | 1.56% |
| 19 | AVTE AEROVATE THERAPEUTICS INC | $26.8M | 1.5% |
| 20 | TARS TARSUS PHARMACEUTICALS INC | $25.7M | 1.44% |
Values as reported on the Q2 2023 Form 13F. Every position is in the holdings table below.